Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
about
Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?Biomarkers in triple negative breast cancer: A reviewImportance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesisEGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.Properties and regulation of the bifunctional enzyme HPr kinase/phosphatase in Bacillus subtilis.Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin.Conventional cytotoxic and novel therapeutic concepts in colorectal cancer.Modulating the structure of EGFR with UV light: new possibilities in cancer therapy.Targeting angiogenesis with integrative cancer therapies.Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf.Tyrosine kinases as targets in cancer therapy - successes and failures.Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.Molecular biological design of novel antineoplastic therapies.Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2.Angiogenesis, immune system and growth factors: new targets in colorectal cancer therapy.Challenges in design and characterization of ligand-targeted drug delivery systems.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.Multifunctional dendritic polymers in nanomedicine: opportunities and challenges.Lapatinib and renal cell carcinoma.Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration.Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.Effects of receptor tyrosine kinase inhibitor A47 on estrogen and growth factor-dependent breast cancer cell proliferation and apoptosis in vitro.Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: identification of divergent growth regulatory pathways.Structure-based drug design and AutoDock study of potential protein tyrosine kinase inhibitors.Effects of growth factors and receptor blockade on gastrointestinal cancer.Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases.Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon.Practical consensus recommendations on ovarian suppression in early breast cancer (adjuvant).
P2860
Q24542471-D3BAE6DC-68BE-4B74-9051-E2C8ED297762Q26775094-E58891D2-A0B6-4F0F-B3B4-498D46FC6C9FQ28593435-A2D33608-8772-41FC-9164-9E3222DB1F00Q33677975-329C8C8C-C5A5-4A54-9897-FBD955618F02Q33931164-65416DFE-48C1-428A-8375-4A025114EE73Q34157299-74723042-167E-4F98-8E9A-EE9602D531AEQ34338431-771FD352-5AAD-4197-8ECE-C80E1884BCB4Q34481446-BE2EF110-61FB-4B79-B09C-AE44C0FCC4D2Q34489245-87AC4E86-EDA4-441B-8B8D-F8116F644B0EQ34495463-60EDD516-3B87-4821-9486-139FC661859DQ34551813-0E401E29-9ED5-4568-85D7-3ED24A055F98Q35095147-9E756C12-8E36-4D66-ABB7-40A29F3921A3Q35154257-77A81D22-1589-4F6A-B16B-B538690DE864Q35160217-D9A96DEE-0D61-4C3C-BBDF-DA10F28FE6DDQ35790781-3728774E-11C6-486C-B5B2-8EC841AF3973Q35840361-1244C9BC-98B7-4892-9CF7-2A7B1E218F70Q36235571-0182097C-94E5-4BD4-BBDE-D9DEB25DDE35Q36346851-6FCD6781-4D48-4806-91F6-B8A3798AC335Q37873453-05A0DB17-DFE0-4A65-83AB-214E291436D3Q37967150-B831F043-505E-4722-AB2F-726E38CA1153Q38033193-D4032322-E673-4BCA-9041-0DD27CD0FC24Q39493031-33EEF560-1074-4BA8-BD93-C24661560D7BQ39885205-981F3B3E-5010-4491-8BB2-F2A19EDAB0F5Q40448827-B0A1FC08-630A-4B4A-810A-73DAB8DBB067Q40761190-D426F1F7-EE05-46BB-9660-7A8486DEBA4BQ40781423-C9EE5E70-AF10-4242-BDC9-B71C57FFB9C5Q42038092-4C4564D3-CC68-4134-BC4C-C5B24F704942Q42239344-FA0E08D4-953E-4C09-AC52-617946F82E70Q42802645-22111598-6A52-4B87-8B30-96CAE5317FA8Q43643744-756FE389-4CF3-4291-97AD-A01C876F52ADQ46770295-39A6F92D-7073-4C79-A4F9-4B308E8A1A15Q53406369-45ABE23D-2BB6-4C9E-9B3E-D4227DCE2DC5Q55403230-93CDD69F-AF3B-4C95-8D90-353FA2298AEB
P2860
Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@ast
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@en
type
label
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@ast
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@en
prefLabel
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@ast
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@en
P1433
P1476
Tyrosine kinase inhibitors tar ...... ly: role as anticancer agents.
@en
P2093
P304
P356
10.2165/00003495-200059040-00003
P577
2000-04-01T00:00:00Z
P6179
1032968092